New blood-based test detects lymph node metastasis in individuals with high-risk T1 colorectal cancer
Scientists at City of Hope, a world-renowned independent research and treatment center for cancer and diabetes, have developed a novel, noninvasive liquid biopsy test for detecting lymph node metastasis in individuals with high-risk T1 colorectal carcinoma. Research on the development of the blood test was reported in a new study published in
Gastroenterology, a journal of the American Gastroenterological Association.
This blood-based test is an example of the theranostic (a term that combines therapeutic and diagnostic ) approach at City of Hope, whose goal is to help every patient receive personalized treatment appropriate for their specific disease. Development of blood-based biopsies to detect and monitor tumors is one of the leading-edge technologies under investigation to help patients with cancer.
IDEAYA Reports Darovasertib (IDE196) Monotherapy Overall Survival Data and Observes Early Partial Responses in Binimetinib Combination in Metastatic Uveal Melanoma
- Darovasertib monotherapy results in 57% 1-year Overall Survival (OS) Rate in predominantly 2L / 3L and heavily pre-treated (out to 7L / 8L) MUM patients, where historical 1-year OS Rate has been reported at 37%
- Darovasertib monotherapy median Overall Survival in MUM is 13.2 months, where historical median OS has been reported at approximately 7 months
- Darovasertib and binimetinib combination reports 2 partial responses (PR), including one confirmed partial response, out of nine evaluable patients with at least 2 post-baseline scans (22%) in MUM; 1 PR patient (-40.5%) is awaiting a confirmatory scan
Saniona AB: Saniona to Present Preclinical Data on SAN903 at the ASPET Annual Meeting at Experimental Biology 2021
April 14, 2021
Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that its research team will present preclinical data on SAN903 in a model of idiopathic pulmonary fibrosis at the American Society of Pharmacology and Experimental Therapeutics (ASPET) Annual Meeting at Experimental Biology (EB) 2021, which is being held virtually between April 27 and 30, 2021.
SAN903 is a novel, potential first-in-class medicine based on inhibition of the calcium-activated potassium ion channel, K
Ca3.1. This ion channel is found in immune cells and fibroblasts, and it controls the proliferation, migration and release of cytokines and collagen. Previous studies have indicated that K
Saniona AB
Saniona to Present Preclinical Data on SAN903 at the ASPET Annual Meeting at Experimental Biology 2021
Saniona to Present Preclinical Data on SAN903 at the ASPET Annual Meeting at Experimental Biology 2021
PRESS RELEASE
April 14, 2021
Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that its research team will present preclinical data on SAN903 in a model of idiopathic pulmonary fibrosis at the American Society of Pharmacology and Experimental Therapeutics (ASPET) Annual Meeting at Experimental Biology (EB) 2021, which is being held virtually between April 27 and 30, 2021.
SAN903 is a novel, potential first-in-class medicine based on inhibition of the calcium-activated potassium ion channel, K
Credit: Kim Ratliff, Augusta University
Augusta University has received a $1.5 million grant from the National Institutes of Health to help support the graduate education of future scientists whose focus is cardiometabolic diseases like hypertension and diabetes which disproportionally affect minorities.
The training grant (1HL155011-01A1) will support four graduate students in its first year, and scale up to six students per year by year four of the five-year grant. It will offer aspiring PhDs and MD/PhDs the opportunity to learn from 43 federally funded scientists focusing on different aspects of cardometabolic disease related to minority health. Student recruitment has just started.